• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    H. Lundbeck (CPSE:HLUN B) After Strong Q2 Results Is The Stock A Bargain Or Priced Right

    Simply Wall St·09/01/2026 15:25:23
    Listen to the news

    Why H. Lundbeck stock is in focus after Q2 2026

    H. Lundbeck (CPSE:HLUN B) is back on investor radars after reporting second quarter 2026 earnings, with higher sales and net income, and confirming full year guidance supported by demand for its key pharmaceutical brands.

    Following the earnings release and confirmed 2026 guidance, H. Lundbeck’s share price, now at DKK42.2, has seen a modest 1-day share price return of 1.88%, while the 90-day share price return is down 4.57%. However, the 3-year total shareholder return of 29.57% suggests momentum has built over a longer horizon as investors reassess both growth potential and risk.

    Compare H. Lundbeck’s post earnings momentum with other healthcare stocks showing resilient growth profiles by scanning our curated 130 healthcare AI stocks for potential ideas.

    H. Lundbeck now trades at a discount to both analyst targets and an intrinsic value estimate, even after the recent share price bounce. Is this simply the market staying cautious, or is that caution starting to look excessive?

    Most Popular Narrative: 13.4% Undervalued

    The most followed narrative currently values H. Lundbeck at DKK48.73 per share, compared with the latest close at DKK42.2. That gap reflects a view that the market is underpricing its future earnings profile even as growth forecasts are conservative.

    A maturing pipeline with 5-6 mid

    to late-stage assets (bexicaserin, amlenetug, D1/D2 agonist) targeting high unmet needs in CNS and neuro-rare diseases, underpins prospects for portfolio diversification and long-term growth, likely driving both revenue and gross margin expansion as late-stage candidates move towards approval.

    Read the complete narrative.

    Want to understand why a declining revenue profile still supports a higher fair value for H. Lundbeck? The narrative leans heavily on margins, earnings resilience and a richer future P/E multiple to bridge that gap.

    Result: Fair Value of DKK48.73 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the H. Lundbeck narrative still hinges on a concentrated drug portfolio and higher R&D and capital spending, which could pressure margins if key programs disappoint.

    Find out about the key risks to this H. Lundbeck narrative.

    Next Steps

    Given the mix of optimism and concern around H. Lundbeck, it makes sense to review the full picture now and form your own view based on both sides of the story with the latest breakdown of 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond H. Lundbeck?

    If H. Lundbeck has sharpened your focus on quality, this is a good moment to widen your search and line up your next set of potential opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.